Nephrol Dial Transplant (2002) 17: 10-15
© 2002 European Renal Association-European Dialysis and Transplant Association
Cardiac effects of chronic inflammation in dialysis patients
Malpighi Nephrology and Dialysis Division, Policlinico S. Orsola-Malpighi, Bologna, Italy
Abstract
Cardiovascular pathology is the major cause of death in uraemia. There is evidence that a chronic inflammation with activation of C-reactive protein, interleukin-6, tumour necrosis factor-
and other cytokines is associated with vascular pathology, both in the general population and in dialysis patients. The cardiovascular system, and particularly the vascular wall, is the main target of the inflammatory process. Inflammation of the coronary arteries could be involved in the development of atherosclerosis and its related clinical syndromes. In the uraemic state, an increased production of pro-inflammatory cytokines may trigger the onset and progression of atherosclerosis and favour the subsequent complications, such as plaque fissuration and rupture. However, inflammatory cytokines also have a depressant action on the myocardium, thus inducing myocardial dysfunction. Together, these conditions may ultimately enhance the risk of myocardial infarction and death. From this standpoint, cardiovascular disease should also be investigated with the traditional biochemical inflammation markers and the evaluation of the circulating cytokine level, although new reliable markers could provide further diagnostic help. New therapeutic approaches should also be considered.
Keywords: acute phase reaction; atherosclerosis; haemodialysis; inflammation; myocardiopathy; uraemia
Notes
Correspondence and offprint requests to: Dr Antonio Santoro, U.O. Nefrologia e Dialisi Malpighi, Policlinico S. Orsola-Malpighi, Via P. Palagi 9, 40138 Bologna, Italy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Di Micco, S. Torraca, A. Pota, D. Di Giuseppe, A. Pisani, L. Spinelli, S. De Portu, M. Sabbatini, L. Mantovani, and B. Cianciaruso Setting dialysis start at 6.0 ml/min/1.73 m2 eGFR--a study on safety, quality of life and economic impact Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3434 - 3440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Jones Pharmacokinetics of vitamin D toxicity Am. J. Clinical Nutrition, August 1, 2008; 88(2): 582S - 586S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C Dennis and G. L Albertson Doxercalciferol Treatment of Secondary Hyperparathyroidism Ann. Pharmacother., November 1, 2006; 40(11): 1955 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bayes, M. C. Pastor, J. Bonal, A. Foraster, and R. Romero Oxidative stress, inflammation and cardiovascular mortality in haemodialysis--role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up Nephrol. Dial. Transplant., April 1, 2006; 21(4): 984 - 990. [Abstract] [Full Text] [PDF]
|
|